Jump to content

Michel Bouvier (scientist)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Nclairoux (talk | contribs) at 19:27, 3 February 2021 (→Honours: Creation of the section and addition of 7 prizes and awards #1Lib1Ref). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Michel Bouvier
Born (1958-09-14) September 14, 1958 (age 66)
CitizenshipCanadian
AwardsFellow of the Academy of Science of the Royal Society of Canada[1]/ Fellow of the Canadian Academy of Health Sciences / Canada Research Chair in Signal Transduction and Molecular Pharmacology[2]
Scientific career
FieldsBiochemistry and molecular pharmacology

Michel Bouvier (born September 14, 1958) is a Canadian biochemist and molecular pharmacologist. He is a professor of biochemistry and molecular medicine at Université de Montréal; a principal investigator and the Chief Executive Officer at the Institute for Research in Immunology and Cancer; and an Associate Vice-President in Research, Scientific Discovery, Creation and Innovation at Université de Montréal. His work focuses on the study of cell signaling towards the discovery of new pharmaceutical drugs.[3]

Biography

Michel Bouvier earned a B.Sc. in Biochemistry (1979) and a Ph.D. in Neurological Sciences (1985) from Université de Montréal, and then completed a post-doctoral fellow (1985-1989) at Duke University under the supervision of Robert Lefkowitz (2012 Nobel Prize in Chemistry[4]). Bouvier is a professor in the Department of Biochemistry and Molecular Medicine at the Faculty of Medicine of Université de Montréal and a principal investigator at the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal.[5]

Research

He is a world-known expert[6][7] in cell signaling and drug discovery, notably in the field of G protein-coupled receptors (GPCRs).[8] GPCRs constitute the largest single protein family involved in the transduction of hormonal signals and neurotransmitters. Their physiological significance makes them a prime target in drug development, and over a third of existing drugs use GPCRs as their target site of action. Bouvier’s work in the regulation of receptors led to new paradigms (inverse agonism; pharmacological chaperones; receptor polymerization; and pluri-dimensionality of signaling), which, coupled with the development of bioluminescence resonance energy transfer (BRET)-based methods, have a direct impact on drug discovery.[9] He has authored over 260 scientific articles,[10] filed 36 patent applications, and delivered over 400 lectures as a guest lecturer. Bouvier holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology[11]

Honours

References

  1. ^ Michel Bouvier at RSC
  2. ^ Research Chair
  3. ^ "Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal (French)". www.biochimie.umontreal.ca.
  4. ^ "Michel Bouvier | FORCES magazine". www.magazineforces.com. Retrieved 1 March 2016.
  5. ^ "Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal (French)". www.biochimie.umontreal.ca. Retrieved 2016-03-01.
  6. ^ "The World's Most Influential Scientific Minds 2014" (PDF). Retrieved 1 March 2016.
  7. ^ User, Super. "Domain Therapeutics, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology". Parc d'Innovation de Strasbourg | Eco-parc d'activité en Alsace. Retrieved 2016-03-01. {{cite web}}: |last= has generic name (help)
  8. ^ "Université de Montréal (via noodls) / Michel Bouvier at the helm of IRIC". www.noodls.com. Retrieved 2016-03-01.
  9. ^ "MICHEL BOUVIER – Canadian Academy of Health Sciences / Académie canadianne des sciences de la santé". cahs-acss.ca. Retrieved 2016-03-01.
  10. ^ "Michel Bouvier". ResearchGate. Retrieved 2016-03-01.
  11. ^ Government of Canada, Industry Canada (2012-11-29). "Canada Research Chairs". Retrieved 2016-03-01.
  12. ^ "Killam Prizes". Killam Program | Building Canada's Future through Research. Retrieved 2021-02-03.{{cite web}}: CS1 maint: url-status (link)
  13. ^ "Prix du Québec – Prix Wilder-Penfield - Récipiendaire". Les Prix du Québec. Retrieved 2021-02-03.{{cite web}}: CS1 maint: url-status (link)
  14. ^ "Julius Axelrod Award in Pharmacology". ASPET. Retrieved 2021-02-03.{{cite web}}: CS1 maint: url-status (link)
  15. ^ "Member Directory | The Royal Society of Canada". rsc-src.ca. Retrieved 2021-02-03.
  16. ^ "Prix Adrien-Pouliot - Contrer le diabète, l'obésité et le cancer ? Rien de moins !". Le Devoir (in French). Retrieved 2021-02-03.
  17. ^ "Prix Léo-Pariseau - Décrypter les protéines G". Le Devoir (in French). Retrieved 2021-02-03.
  18. ^ "CAHS Fellows Directory – Canadian Academy of Health Sciences". Retrieved 2021-02-03.{{cite web}}: CS1 maint: url-status (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Michel_Bouvier_(scientist)&oldid=1004664955"